Drugs and designated type of cancer |
No. of applications approved |
Amount of subsidies granted (HK Dollar) |
Pemetrexed N4 for treating lung cancer |
2,362 |
$87.79M |
Sunitinib for treating gastrointestinal tumour |
209 |
$16.84M |
Sunitinib for treating renal cell carcinoma |
369 |
$24.92M |
Pegylated liposomal Doxorubicin for treating ovarian cancer |
316 |
$14.22M |
Lapatinib for treating breast cancer |
615 |
$31.18M |
CetuximabN2for treating colorectal cancer |
163 |
$15.57M |
RituximabN1for treating leukaemia |
22 |
$1.10M |
DasatinibN1for treating leukaemia |
5 |
$0.16M |
GefitinibN3 for treating lung cancer |
3,227 |
$271.37M |
Sorafenib for treating liver cancer |
2,155 |
$72.84M |
ErlotinibN3for treating lung cancer |
1,745 |
$141.14M |
PazopanibN5for treating renal cell carcinoma |
254 |
$24.85M |
AfatinibN3for treating lung cancer |
129 |
$11.81M |
BendamustineN6for treating leukaemia |
22 |
$3.18M |
TrastuzumabN6for treating gastric carcinoma |
32 |
$4.58M |
VemurafenibN6for treating skin cancer |
16 |
$2.47M |
Bevacizumab for treating epithelial ovarian / fallopian tube / primary peritoneal cancer N7 |
91 |
$13.08M |
PertuzumabN7 for treating breast cancer |
318 |
$116.55M |
AbirateroneN14 for treating Prostate cancer |
91 |
$10.33M |
EnzalutamideN12 for treating Prostate cancer |
170 |
$22.19M |
NivolumabN8for treating skin cancer |
31 |
$8.73M |
ObinutuzumabN8for treating chronic lymphocytic leukaemia |
14 |
$1.62M |
BevacizumabN9for treating colorectal cancer |
510 |
$54.32M |
AxitinibN10for treating renal cell carcinoma |
26 |
$1.21M |
AlectinibN10for treating lung cancer |
42 |
$11.80M |
CeritinibN10for treating lung cancer |
17 |
$2.05M |
OsimertinibN10for treating lung cancer |
185 |
$48.73M |
PalbociclibN10for treating breast cancer |
131 |
$27.73M |
EverolimusN10for treating breast cancer |
26 |
$3.49M |
Trastuzumab emtansineN10for treating breast cancer |
61 |
$15.48M |
RibociclibN11for treating breast cancer |
21 |
$3.99M |
Dabrafenib and TrametinibN13for treating skin cancer |
0 |
$0M |
Total |
13,375 |
$1,065.32M |
N1 |
Repositioned to the Samaritan Fund with effect from 13 April 2013 and the above figures are based on the actual drug expenditure. |
N2 |
Repositioned to the Samaritan Fund with effect from 1 August 2016 and the above figures are based on the actual drug expenditure. |
N3 |
Repositioned to the Samaritan Fund with effect from 16 February 2019 and the above figures are based on the actual drug expenditure. |
N4 |
Repositioned to the Special Drugs under HA Drug Formulary with effect from 13 April 2019 and the above figures are based on the actual drug expenditure. |
N5 |
Introduced to the First Phase Programme with effect from 1 August 2015. |
N6 |
Introduced to the First Phase Programme with effect from 1 August 2016. |
N7 |
Introduced to the First Phase Programme with effect from 1 August 2017. |
N8 |
Introduced to the First Phase Programme with effect from 1 August 2018. |
N9 |
Introduced to the First Phase Programme with effect from 1 August 2013 and indication extended with effect from 1 August 2018. |
N10 |
Introduced to the First Phase Programme with effect from 16 February 2019. |
N11 |
Introduced to the First Phase Programme with effect from 13 July 2019. |
N12 |
Introduced to the First Phase Programme with effect from 1 August 2017 and indication extended with effect from 13 July 2019. |
N13 |
Introduced to the First Phase Programme with effect from 11 January 2020. |
N14 |
Introduced to the First Phase Programme with effect from 1 August 2017 and indication extended with effect from 11 January 2020. |